Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases

[Business Wire] – Gilead Sciences, Inc. and Phenex Pharmaceuticals AG, a privately-held biotechnology company, today announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor program comprising . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases Similar Articles: Stock Update (NASDAQ:GILD): Gilead Sciences Announces Third Quarter 2014 Financial Results Market Update (NASDAQ:GILD): Gilead Sciences to Present at Two Upcoming Investor Conferences in September Microsoft Corporation (NASDAQ:MSFT) – Microsoft announces winners and finalists of 2014 Sales Achievement program